61 results
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
11 Oct 23
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
5:03pm
, as we work to create significant value for shareholders. Dr. Mahony’s lifetime commitment to helping patients with serious conditions will advance our
424B5
AXSM
Axsome Therapeutics Inc
28 Jun 23
Prospectus supplement for primary offering
8:16pm
, the underwriters will acquire the securities for their own account for resale to the public, either on a firm commitment basis or a best efforts basis
424B5
AXSM
Axsome Therapeutics Inc
27 Jun 23
Prospectus supplement for primary offering
8:51pm
, either on a firm commitment basis or a best efforts basis. The underwriters may resell the securities in one or more transactions, including negotiated
S-3ASR
hzcy79
2 Dec 22
Automatic shelf registration
5:27pm
8-K
EX-99.1
m7blz5 c31682d6e8g7
20 Oct 22
Other Events
7:05am
424B5
l6n8rbjp3 qrfix
19 Aug 22
Prospectus supplement for primary offering
9:35pm
8-K
EX-99.1
z83w4l
19 Aug 22
Other Events
7:05am
8-K
EX-99.1
o2opcr xfm32yntc
9 May 22
Completion of Acquisition or Disposition of Assets
7:05am
8-K/A
EX-99.1
im9n62h08u470tc2ww
31 Mar 22
Asset Purchase Agreement
4:45pm
8-K
EX-99.2
0zqu nt6ytr
28 Mar 22
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
8:00am
424B5
1d7xyg2
1 Mar 22
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
tirn45vj9vxendy
18 Oct 21
Entry into a Material Definitive Agreement
7:05am